Conceptio › Archive › HAL (France)
HAL (France)open access

Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMel

Stéphane Dalle et al.
HAL (France) · Papers · License: Open Access
Open Source ↗
immunotherapyreal
Nivolumab, Real-world evidence, Advanced melanoma, 0, Lines of therapy, Immunotherapy
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 624886
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.